John R Teerlink Selected Research

Purinergic P1 Receptor Antagonists

11/2019	Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
1/2018	Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion: A Post Hoc Analysis of the PROTECT Data.
1/2017	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure.
1/2016	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure.
5/2015	Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies.
1/2014	Renal function trajectories and clinical outcomes in acute heart failure.
1/2014	Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study.
11/2011	Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study.
5/2011	Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John R Teerlink Research Topics

Disease

189	Heart Failure 05/2022 - 05/2002
17	Dyspnea (Shortness of Breath) 01/2019 - 02/2003
14	Renal Insufficiency (Renal Failure) 01/2020 - 04/2009
9	Stroke (Strokes) 12/2019 - 03/2012
8	Systolic Heart Failure 01/2021 - 08/2011
7	Weight Loss (Weight Reduction) 01/2022 - 04/2010
7	Hypertension (High Blood Pressure) 01/2018 - 12/2009
6	Myocardial Infarction 01/2022 - 03/2002
6	Heart Diseases (Heart Disease) 03/2021 - 10/2013
6	Hypotension (Low Blood Pressure) 01/2020 - 07/2003
6	Ischemic Stroke 10/2016 - 05/2012
5	Disease Progression 01/2021 - 10/2010
5	Ischemia 01/2017 - 11/2004
5	Left Ventricular Dysfunction 02/2015 - 06/2006
4	Ventricular Remodeling 01/2017 - 12/2002
4	Hemorrhage 09/2015 - 05/2012
3	Atrial Fibrillation 01/2022 - 02/2012
3	Cardiomyopathies (Cardiomyopathy) 01/2022 - 11/2017
3	Cardiac Arrhythmias (Arrythmia) 08/2021 - 04/2013
3	Cardiovascular Diseases (Cardiovascular Disease) 06/2019 - 01/2016
3	Inflammation (Inflammations) 10/2017 - 10/2016
3	Edema (Dropsy) 08/2017 - 11/2007
3	Cerebral Hemorrhage 01/2016 - 01/2013
2	Cardiogenic Shock 08/2021 - 01/2019
2	Low Cardiac Output 01/2019 - 10/2011
2	Body Weight (Weight, Body) 01/2019 - 05/2011
2	Diabetes Mellitus 10/2017 - 01/2016

Drug/Important Bio-Agent (IBA)

24	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 10/2006
19	DiureticsIBA 01/2022 - 05/2004
19	Biomarkers (Surrogate Marker)IBA 03/2021 - 02/2003
18	omecamtiv mecarbilIBA 05/2022 - 12/2009
14	rolofyllineIBA 11/2019 - 10/2010
13	Cardiac MyosinsIBA 01/2022 - 12/2009
13	RelaxinIBA 12/2021 - 04/2009
13	Warfarin (Coumadin)FDA LinkGeneric 04/2019 - 05/2012
13	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 04/2019 - 05/2012
12	Pharmaceutical PreparationsIBA 10/2021 - 01/2010
11	Natriuretic PeptidesIBA 01/2022 - 03/2016
9	Purinergic P1 Receptor AntagonistsIBA 11/2019 - 05/2011
9	Urea (Carbamide)FDA LinkGeneric 01/2017 - 01/2014
8	CreatinineIBA 01/2022 - 01/2013
8	NitrogenIBA 01/2017 - 01/2014
7	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2019 - 08/2005
7	tezosentanIBA 01/2017 - 07/2003
6	sacubitril and valsartan sodium hydrate drug combinationIBA 11/2020 - 01/2015
6	Neprilysin (Neutral Endopeptidase)IBA 06/2019 - 01/2015
6	Angiotensin Receptors (Angiotensin II Receptor)IBA 06/2019 - 01/2015
6	Vasodilator Agents (Vasodilators)IBA 01/2017 - 05/2004
5	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 11/2019 - 08/2005
5	Angiotensin Receptor AntagonistsIBA 11/2019 - 08/2005
5	Endothelin Receptors (Endothelin Receptor)IBA 01/2017 - 07/2005
5	TroponinIBA 01/2017 - 01/2011
5	Tolvaptan FDA Link 01/2016 - 05/2004
5	Troponin T (Troponin T1)IBA 01/2016 - 11/2011
4	empagliflozinIBA 01/2022 - 01/2021
4	Furosemide (Lasix)FDA LinkGeneric 01/2022 - 05/2014
4	Sodium-Glucose Transport ProteinsIBA 01/2022 - 12/2019
4	Enalapril FDA LinkGeneric 10/2017 - 01/2015
4	Simendan (Levosimendan)IBA 04/2013 - 05/2004
4	Adenosine (Adenocard)FDA LinkGeneric 03/2012 - 05/2004
4	Vasoconstrictor AgentsIBA 06/2008 - 05/2002
4	Neurotransmitter Agents (Neurotransmitter)IBA 12/2005 - 05/2002
4	Endothelins (Endothelin)IBA 12/2005 - 05/2002
3	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 01/2021
3	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 01/2022 - 06/2013
3	IvabradineIBA 11/2021 - 09/2010
3	PotassiumIBA 11/2021 - 01/2017
3	SodiumIBA 01/2021 - 01/2014
3	Nitroglycerin (Dynamite)FDA LinkGeneric 01/2021 - 05/2004
3	Myosins (Myosin)IBA 12/2020 - 12/2016
3	Mineralocorticoid Receptor AntagonistsIBA 11/2019 - 04/2012
3	LigandsIBA 02/2018 - 03/2015
3	MicroRNAs (MicroRNA)IBA 12/2016 - 01/2016
3	Adenosine A1 ReceptorIBA 11/2016 - 05/2011
3	Hemoglobins (Hemoglobin)IBA 02/2016 - 05/2013
3	Vasopressins (Vasopressin)IBA 01/2016 - 05/2004
3	Milrinone (Primacor)FDA LinkGeneric 10/2011 - 05/2004
3	Endothelin-1 (Endothelin 1)IBA 01/2011 - 07/2005
3	Endothelin Receptor AntagonistsIBA 11/2007 - 12/2002
2	Plant NectarIBA 01/2022 - 01/2020
2	Oxygen (Dioxygen)IBA 08/2021 - 01/2019
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 01/2011
2	nitroxylIBA 01/2021 - 01/2019
2	Biological ProductsIBA 01/2021 - 01/2019
2	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2010
2	Hypoglycemic Agents (Hypoglycemics)IBA 12/2019 - 10/2017
2	Sar-Arg-Val-Tyr-Ile-His-Pro-Ala-OHIBA 02/2018 - 03/2015
2	Type 1 Angiotensin ReceptorIBA 02/2018 - 08/2017
2	salicylhydroxamic acid (SHAM)IBA 11/2017 - 03/2017
2	C-Reactive ProteinIBA 02/2016 - 01/2011
2	AlbuminsIBA 01/2016 - 01/2014
2	Irbesartan FDA LinkGeneric 06/2015 - 03/2010

Therapy/Procedure

61	Therapeutics 01/2022 - 02/2003
24	Patient Readmission 01/2022 - 04/2010
16	Length of Stay 01/2020 - 01/2010
3	Critical Care (Surgical Intensive Care) 10/2021 - 01/2015
3	Intravenous Infusions 01/2019 - 01/2013
2	Vagus Nerve Stimulation 01/2022 - 01/2020
2	Heart Transplantation (Grafting, Heart) 09/2019 - 01/2015
2	Investigational Therapies (Experimental Therapy) 11/2015 - 02/2015